Healthcare -
Biotechnology - NASDAQ - US
$ 15.85
5.46 %
$ 482 M
Market Cap
-2.62
P/E
1. INTRINSIC VALUE
Balance Sheet
AnaptysBio, Inc.
| Current Assets | 407 M |
| Cash & Short-Term Investments | 391 M |
| Receivables | 6.85 M |
| Other Current Assets | 9.08 M |
| Non-Current Assets | 45.6 M |
| Long-Term Investments | 27 M |
| PP&E | 18.3 M |
| Other Non-Current Assets | 256 K |
| Current Liabilities | 37.4 M |
| Accounts Payable | 4.7 M |
| Short-Term Debt | 1.78 M |
| Other Current Liabilities | 31 M |
| Non-Current Liabilities | 327 M |
| Long-Term Debt | 16 M |
| Other Non-Current Liabilities | 311 M |
EFFICIENCY
Earnings Waterfall
AnaptysBio, Inc.
| Revenue | 17.2 M |
| Cost Of Revenue | 2.38 M |
| Gross Profit | 14.8 M |
| Operating Expenses | 182 M |
| Operating Income | -164 M |
| Other Expenses | -792 K |
| Net Income | -164 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
AnaptysBio, Inc.
| Net Income | -164 M |
| Depreciation & Amortization | 2.38 M |
| Capital Expenditures | -807 K |
| Stock-Based Compensation | 33.2 M |
| Change in Working Capital | -324 K |
| Others | -3.7 M |
| Free Cash Flow | -122 M |
Wall Street Analysts Price Targets
AnaptysBio, Inc.
Wall Street analysts predict an average 1-year price target for ANAB of $49.8 , with forecasts ranging from
a
low of
$19 to a high of $90 .
ANAB Lowest Price Target
Wall Street Target
19 USD
19.87%
ANAB Average Price Target
Wall Street Target
49.8 USD
213.88%
ANAB Highest Price Target
Wall Street Target
90 USD
467.82%
4. DIVIDEND
ANALYSIS
ANAB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
AnaptysBio, Inc.
Sold
0-3 MONTHS
250 K USD 1
3-6 MONTHS
1.26 M USD 3
6-9 MONTHS
432 K USD 3
9-12 MONTHS
3.59 M USD 3
Bought
1.1 M USD 1
0-3 MONTHS
10 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
2 weeks ago
Jan 02, 2025
|
Bought
86.1 K USD
|
EcoR1 Capital, LLC
director, 10 percent owner:
|
+ 6646
|
12.9506 USD |
|
2 weeks ago
Dec 31, 2024
|
Bought
172 K USD
|
EcoR1 Capital, LLC
director, 10 percent owner:
|
+ 13268
|
12.9268 USD |
|
2 weeks ago
Dec 30, 2024
|
Bought
842 K USD
|
EcoR1 Capital, LLC
director, 10 percent owner:
|
+ 65184
|
12.9182 USD |
|
1 month ago
Nov 29, 2024
|
Sell 250 K
USD
|
RENTON HOLLINGS
Director
|
- 10000
|
25 USD |
|
3 months ago
Sep 23, 2024
|
Sell 58 K
USD
|
Lizzul Paul F.
Chief Medical Officer
|
- 1500
|
38.67 USD |
|
4 months ago
Sep 16, 2024
|
Sell 86.4 K
USD
|
LOUMEAU ERIC J
CHIEF LEGAL OFFICER
|
- 2220
|
38.93 USD |
|
4 months ago
Sep 16, 2024
|
Sell 261 K
USD
|
LOUMEAU ERIC J
CHIEF LEGAL OFFICER
|
- 6500
|
40.13 USD |
|
4 months ago
Sep 17, 2024
|
Sell 145 K
USD
|
LOUMEAU ERIC J
CHIEF LEGAL OFFICER
|
- 3780
|
38.4103 USD |
|
4 months ago
Sep 16, 2024
|
Sell 86.4 K
USD
|
Lizzul Paul F.
Chief Medical Officer
|
- 2220
|
38.93 USD |
|
4 months ago
Sep 16, 2024
|
Sell 86.4 K
USD
|
MULROY DENNIS
CHIEF FINANCIAL OFFICER
|
- 2220
|
38.93 USD |
|
4 months ago
Sep 16, 2024
|
Sell 401 K
USD
|
MULROY DENNIS
CHIEF FINANCIAL OFFICER
|
- 10000
|
40.13 USD |
|
5 months ago
Aug 14, 2024
|
Sell 80 K
USD
|
Lizzul Paul F.
Chief Medical Officer
|
- 2000
|
40 USD |
|
5 months ago
Aug 14, 2024
|
Bought
10 M USD
|
EcoR1 Capital, LLC
10 percent owner
|
+ 273972
|
36.5 USD |
|
6 months ago
Jul 18, 2024
|
Sell 52.5 K
USD
|
Lizzul Paul F.
Chief Medical Officer
|
- 1500
|
35 USD |
|
6 months ago
Jul 15, 2024
|
Sell 217 K
USD
|
RENTON HOLLINGS
Director
|
- 7103
|
30.5038 USD |
|
6 months ago
Jul 15, 2024
|
Sell 89.8 K
USD
|
RENTON HOLLINGS
Director
|
- 2897
|
30.9817 USD |
|
6 months ago
Jun 21, 2024
|
Sell 45.2 K
USD
|
FENTON DENNIS M
Director
|
- 1950
|
23.17 USD |
|
7 months ago
Jun 18, 2024
|
Sell 45.2 K
USD
|
RENTON HOLLINGS
Director
|
- 1950
|
23.16 USD |
|
7 months ago
May 22, 2024
|
Sell 35.6 K
USD
|
MULROY DENNIS
CHIEF FINANCIAL OFFICER
|
- 1500
|
23.72 USD |
|
9 months ago
Mar 22, 2024
|
Sell 3.33 M
USD
|
Faga Daniel
CEO
|
- 145940
|
22.7846 USD |
|
9 months ago
Mar 25, 2024
|
Sell 64.3 K
USD
|
Faga Daniel
CEO
|
- 3000
|
21.4225 USD |
|
11 months ago
Feb 16, 2024
|
Sell 125 K
USD
|
LOUMEAU ERIC J
CHIEF LEGAL OFFICER
|
- 5000
|
25 USD |
|
11 months ago
Jan 30, 2024
|
Sell 72.4 K
USD
|
MULROY DENNIS
CHIEF FINANCIAL OFFICER
|
- 3065
|
23.6298 USD |
|
1 year ago
Jan 08, 2024
|
Sell 55.7 K
USD
|
Lizzul Paul F.
Chief Medical Officer
|
- 2554
|
21.81 USD |
|
1 year ago
Jan 08, 2024
|
Sell 50.3 K
USD
|
LOUMEAU ERIC J
Chief Legal Officer
|
- 2305
|
21.81 USD |
|
1 year ago
Jan 08, 2024
|
Sell 47.5 K
USD
|
MULROY DENNIS
Chief Financial Officer
|
- 2180
|
21.81 USD |
|
1 year ago
Jan 08, 2024
|
Sell 150 K
USD
|
Faga Daniel
CEO
|
- 6866
|
21.81 USD |
|
1 year ago
Nov 22, 2023
|
Sell 12.5 K
USD
|
LOUMEAU ERIC J
Chief Legal Officer
|
- 882
|
14.19 USD |
|
1 year ago
Sep 14, 2023
|
Sell 41 K
USD
|
Lizzul Paul F.
Chief Medical Officer
|
- 2105
|
19.48 USD |
|
1 year ago
Sep 14, 2023
|
Sell 41 K
USD
|
LOUMEAU ERIC J
Chief Legal Officer
|
- 2105
|
19.48 USD |
|
1 year ago
Sep 18, 2023
|
Sell 75.2 K
USD
|
LOUMEAU ERIC J
Chief Legal Officer
|
- 3895
|
19.3151 USD |
|
1 year ago
Sep 14, 2023
|
Sell 41 K
USD
|
MULROY DENNIS
Chief Financial Officer
|
- 2105
|
19.48 USD |
|
1 year ago
Sep 18, 2023
|
Sell 75.2 K
USD
|
MULROY DENNIS
Chief Financial Officer
|
- 3895
|
19.3162 USD |
|
2 years ago
Aug 08, 2022
|
Sell 13.1 K
USD
|
LOUMEAU ERIC J
COO, General Counsel
|
- 523
|
25 USD |
|
2 years ago
Jun 08, 2022
|
Sell 60 K
USD
|
LOUMEAU ERIC J
COO, General Counsel
|
- 2500
|
24 USD |
|
2 years ago
May 18, 2022
|
Sell 23.5 K
USD
|
LOUMEAU ERIC J
COO, General Counsel
|
- 1146
|
20.5 USD |
|
2 years ago
May 05, 2022
|
Sell 14.5 M
USD
|
NODELMAN OLEG
director:
|
- 668237
|
21.63 USD |
|
2 years ago
May 05, 2022
|
Bought
14.5 M USD
|
NODELMAN OLEG
director:
|
+ 668237
|
21.63 USD |
|
2 years ago
May 05, 2022
|
Bought
14.5 M USD
|
EcoR1 Capital, LLC
10 percent owner
|
+ 668237
|
21.63 USD |
|
2 years ago
May 05, 2022
|
Sell 14.5 M
USD
|
EcoR1 Capital, LLC
10 percent owner
|
- 668237
|
21.63 USD |
|
3 years ago
Dec 20, 2021
|
Sell 416 K
USD
|
Suria Hamza
President, CEO
|
- 11915
|
34.8935 USD |
|
3 years ago
Dec 20, 2021
|
Sell 687 K
USD
|
Suria Hamza
President, CEO
|
- 19208
|
35.7547 USD |
|
3 years ago
Dec 20, 2021
|
Sell 201 K
USD
|
Suria Hamza
President, CEO
|
- 5522
|
36.4046 USD |
|
3 years ago
Nov 05, 2021
|
Sell 501 K
USD
|
Suria Hamza
President, CEO
|
- 14302
|
35 USD |
|
3 years ago
Nov 04, 2021
|
Sell 175 K
USD
|
LOUMEAU ERIC J
COO, General Counsel
|
- 5000
|
35 USD |
|
3 years ago
Nov 01, 2021
|
Sell 1.1 M
USD
|
Suria Hamza
President, CEO
|
- 34087
|
32.2694 USD |
|
3 years ago
Nov 01, 2021
|
Sell 84.1 K
USD
|
Suria Hamza
President, CEO
|
- 2559
|
32.8798 USD |
|
3 years ago
Oct 26, 2021
|
Sell 480 K
USD
|
Suria Hamza
President, CEO
|
- 15993
|
30 USD |
|
3 years ago
May 04, 2021
|
Bought
3.84 M USD
|
EcoR1 Capital, LLC
director, 10 percent owner:
|
+ 165000
|
23.247 USD |
|
3 years ago
May 03, 2021
|
Bought
485 K USD
|
EcoR1 Capital, LLC
director, 10 percent owner:
|
+ 20800
|
23.3112 USD |
|
3 years ago
Apr 30, 2021
|
Bought
827 K USD
|
EcoR1 Capital, LLC
director, 10 percent owner:
|
+ 35700
|
23.1601 USD |
|
3 years ago
Apr 27, 2021
|
Bought
805 K USD
|
EcoR1 Capital, LLC
director, 10 percent owner:
|
+ 33800
|
23.8192 USD |
|
3 years ago
Apr 26, 2021
|
Bought
331 K USD
|
EcoR1 Capital, LLC
director, 10 percent owner:
|
+ 13900
|
23.8028 USD |
|
3 years ago
Apr 23, 2021
|
Bought
2.34 M USD
|
EcoR1 Capital, LLC
director, 10 percent owner:
|
+ 99600
|
23.537 USD |
|
3 years ago
Mar 09, 2021
|
Bought
9.93 M USD
|
EcoR1 Capital, LLC
10 percent owner
|
+ 531000
|
18.6976 USD |
|
3 years ago
Mar 08, 2021
|
Bought
52.7 M USD
|
EcoR1 Capital, LLC
10 percent owner
|
+ 2777800
|
18.9698 USD |
|
3 years ago
Feb 23, 2021
|
Bought
752 K USD
|
EcoR1 Capital, LLC
10 percent owner
|
+ 29500
|
25.4799 USD |
|
3 years ago
Feb 12, 2021
|
Sell 350 K
USD
|
LOUMEAU ERIC J
COO, General Counsel
|
- 10000
|
35 USD |
|
5 years ago
Dec 10, 2019
|
Bought
50.6 K USD
|
Ware J. Anthony
Director
|
+ 3600
|
14.05 USD |
|
5 years ago
Jun 10, 2019
|
Sell 620 K
USD
|
Suria Hamza
President, CEO
|
- 8540
|
72.6446 USD |
|
5 years ago
Jun 10, 2019
|
Sell 475 K
USD
|
Suria Hamza
President, CEO
|
- 6440
|
73.7014 USD |
|
5 years ago
Jun 10, 2019
|
Sell 373 K
USD
|
Suria Hamza
President, CEO
|
- 5000
|
74.6825 USD |
|
5 years ago
Jun 10, 2019
|
Sell 151 K
USD
|
Suria Hamza
President, CEO
|
- 1994
|
75.863 USD |
|
5 years ago
Jun 10, 2019
|
Sell 34.6 K
USD
|
Suria Hamza
President, CEO
|
- 454
|
76.31 USD |
|
5 years ago
Jun 04, 2019
|
Sell 435 K
USD
|
Londei Marco
Chief Medical Officer
|
- 6009
|
72.4511 USD |
|
5 years ago
Jun 04, 2019
|
Sell 150 K
USD
|
Londei Marco
Chief Medical Officer
|
- 2048
|
73.4296 USD |
|
5 years ago
Jun 04, 2019
|
Sell 149 K
USD
|
Londei Marco
Chief Medical Officer
|
- 2003
|
74.4978 USD |
|
6 years ago
Jan 14, 2019
|
Sell 1.96 M
USD
|
Suria Hamza
President, CEO
|
- 27760
|
70.6494 USD |
|
6 years ago
Jan 14, 2019
|
Sell 870 K
USD
|
Suria Hamza
President, CEO
|
- 12240
|
71.1033 USD |
|
6 years ago
Jan 15, 2019
|
Sell 290 K
USD
|
Londei Marco
Chief Medical Officer
|
- 4181
|
69.2864 USD |
|
6 years ago
Jan 15, 2019
|
Sell 1.04 M
USD
|
Londei Marco
Chief Medical Officer
|
- 14894
|
70.0413 USD |
|
6 years ago
Dec 17, 2018
|
Sell 792 K
USD
|
Londei Marco
Chief Medical Officer
|
- 12120
|
65.3612 USD |
|
6 years ago
Dec 17, 2018
|
Sell 211 K
USD
|
Londei Marco
Chief Medical Officer
|
- 3185
|
66.3787 USD |
|
6 years ago
Dec 17, 2018
|
Sell 541 K
USD
|
Londei Marco
Chief Medical Officer
|
- 8002
|
67.5686 USD |
|
6 years ago
Dec 17, 2018
|
Sell 462 K
USD
|
Londei Marco
Chief Medical Officer
|
- 6741
|
68.4732 USD |
|
6 years ago
Dec 14, 2018
|
Sell 1.71 M
USD
|
Suria Hamza
President, CEO
|
- 24844
|
68.887 USD |
|
6 years ago
Dec 14, 2018
|
Sell 633 K
USD
|
Suria Hamza
President, CEO
|
- 9084
|
69.6794 USD |
|
6 years ago
Dec 14, 2018
|
Sell 550 K
USD
|
Suria Hamza
President, CEO
|
- 7800
|
70.5101 USD |
|
6 years ago
Dec 10, 2018
|
Sell 1.08 M
USD
|
Suria Hamza
President, CEO
|
- 15276
|
70.5736 USD |
|
6 years ago
Dec 12, 2018
|
Sell 853 K
USD
|
Suria Hamza
President, CEO
|
- 12003
|
71.1056 USD |
|
6 years ago
Dec 10, 2018
|
Sell 740 K
USD
|
Suria Hamza
President, CEO
|
- 10347
|
71.4894 USD |
|
6 years ago
Dec 12, 2018
|
Sell 696 K
USD
|
Suria Hamza
President, CEO
|
- 9673
|
71.9237 USD |
|
6 years ago
Dec 10, 2018
|
Sell 360 K
USD
|
Suria Hamza
President, CEO
|
- 4964
|
72.4829 USD |
|
6 years ago
Dec 11, 2018
|
Sell 354 K
USD
|
Suria Hamza
President, CEO
|
- 4998
|
70.83 USD |
|
6 years ago
Dec 12, 2018
|
Sell 607 K
USD
|
Suria Hamza
President, CEO
|
- 8324
|
72.8758 USD |
|
6 years ago
Dec 03, 2018
|
Sell 250 K
USD
|
Piscitelli Dominic
Chief Financial Officer
|
- 3554
|
70.336 USD |
|
6 years ago
Dec 03, 2018
|
Sell 1.33 M
USD
|
Piscitelli Dominic
Chief Financial Officer
|
- 18604
|
71.332 USD |
|
6 years ago
Dec 03, 2018
|
Sell 348 K
USD
|
Piscitelli Dominic
Chief Financial Officer
|
- 4820
|
72.2432 USD |
|
6 years ago
Dec 03, 2018
|
Sell 168 K
USD
|
Piscitelli Dominic
Chief Financial Officer
|
- 2298
|
73.1761 USD |
|
6 years ago
Dec 03, 2018
|
Sell 492 K
USD
|
Piscitelli Dominic
Chief Financial Officer
|
- 6624
|
74.33 USD |
|
6 years ago
Dec 03, 2018
|
Sell 83.4 K
USD
|
Piscitelli Dominic
Chief Financial Officer
|
- 1100
|
75.8091 USD |
|
6 years ago
Apr 16, 2018
|
Sell 219 K
USD
|
Lydon Nicholas
Director
|
- 2600
|
84.1846 USD |
|
6 years ago
Apr 16, 2018
|
Sell 877 K
USD
|
Lydon Nicholas
Director
|
- 10310
|
85.1107 USD |
|
6 years ago
Apr 16, 2018
|
Sell 120 K
USD
|
Lydon Nicholas
Director
|
- 1390
|
86.1532 USD |
|
6 years ago
Apr 16, 2018
|
Sell 824 K
USD
|
Lydon Nicholas
Director
|
- 9425
|
87.4632 USD |
|
6 years ago
Apr 16, 2018
|
Sell 375 K
USD
|
Lydon Nicholas
Director
|
- 4250
|
88.2982 USD |
|
6 years ago
Apr 16, 2018
|
Sell 251 K
USD
|
Lydon Nicholas
Director
|
- 2803
|
89.4154 USD |
|
6 years ago
Apr 16, 2018
|
Sell 201 K
USD
|
Lydon Nicholas
Director
|
- 2222
|
90.2561 USD |
|
7 years ago
Aug 21, 2017
|
Sell 7.52 M
USD
|
Novo Holdings A/S
10 percent owner
|
- 356300
|
21.1009 USD |
|
7 years ago
Aug 14, 2017
|
Sell 766 K
USD
|
Novo Holdings A/S
10 percent owner
|
- 35172
|
21.7927 USD |
|
7 years ago
Aug 15, 2017
|
Sell 3.01 M
USD
|
Novo Holdings A/S
10 percent owner
|
- 143428
|
21 USD |
|
7 years ago
Aug 04, 2017
|
Sell 226 K
USD
|
Novo Holdings A/S
10 percent owner
|
- 10271
|
22.0001 USD |
|
7 years ago
Aug 07, 2017
|
Sell 10.1 M
USD
|
Novo Holdings A/S
10 percent owner
|
- 480000
|
21.1 USD |
|
7 years ago
Aug 07, 2017
|
Sell 23.4 K
USD
|
Novo Holdings A/S
10 percent owner
|
- 1023
|
22.9155 USD |
|
7 years ago
Aug 01, 2017
|
Sell 562 K
USD
|
Novo Holdings A/S
10 percent owner
|
- 23555
|
23.8705 USD |
|
7 years ago
Aug 02, 2017
|
Sell 613 K
USD
|
Novo Holdings A/S
10 percent owner
|
- 25700
|
23.871 USD |
|
7 years ago
Aug 03, 2017
|
Sell 472 K
USD
|
Novo Holdings A/S
10 percent owner
|
- 21451
|
22.0126 USD |
|
7 years ago
Jul 26, 2017
|
Sell 902 K
USD
|
Avalon Ventures VII L P
10 percent owner
|
- 37040
|
24.35 USD |
|
7 years ago
Jan 31, 2017
|
Bought
750 K USD
|
Novo A/S
10 percent owner
|
+ 50000
|
15 USD |
|
7 years ago
Jan 31, 2017
|
Bought
4.67 M USD
|
Topper James N
director, 10 percent owner:
|
+ 311291
|
15 USD |
|
7 years ago
Jan 31, 2017
|
Bought
1.33 M USD
|
Topper James N
director, 10 percent owner:
|
+ 88709
|
15 USD |
|
7 years ago
Jan 31, 2017
|
Bought
250 K USD
|
Lydon Nicholas
Director
|
+ 16666
|
15 USD |
|
7 years ago
Jan 31, 2017
|
Bought
4.67 M USD
|
Frazier Healthcare VII, L.P.
10 percent owner
|
+ 311291
|
15 USD |
|
7 years ago
Jan 31, 2017
|
Bought
1.33 M USD
|
Frazier Healthcare VII, L.P.
10 percent owner
|
+ 88709
|
15 USD |
|
7 years ago
Jan 31, 2017
|
Bought
4.67 M USD
|
Frazier Healthcare V, LP
10 percent owner
|
+ 311291
|
15 USD |
|
7 years ago
Jan 31, 2017
|
Bought
1.33 M USD
|
Frazier Healthcare V, LP
10 percent owner
|
+ 88709
|
15 USD |
7. News
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025 at 4:30pm PT / 7:30pm ET.
globenewswire.com
- 1 week ago
AnaptysBio Stock Down as Eczema Study Fails to Meet Goals
Phase IIb study on ANAB's ANB032 for atopic dermatitis fails to meet goals. The company decides to discontinue any further investment in the candidate.
zacks.com
- 1 month ago
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
On Wednesday, AnaptysBio, Inc. ANAB announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema.
benzinga.com
- 1 month ago
AnaptysBio to abandon eczema drug development after mid-stage trial failure
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a mid-stage trial, the company said on Wednesday, dragging its shares nearly 40% lower.
reuters.com
- 1 month ago
AnaptysBio abandons eczema drug development after mid-stage trial failure
AnaptysBio said on Wednesday that it would discontinue the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.
reuters.com
- 1 month ago
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. ANB032 was well tolerated with no safety signals observed.
globenewswire.com
- 1 month ago
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Here is how AnaptysBio, Inc. (ANAB) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?
AnaptysBio (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
zacks.com
- 2 months ago
Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB)
The heavy selling pressure might have exhausted for AnaptysBio (ANAB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
zacks.com
- 2 months ago
AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.14 per share versus the Zacks Consensus Estimate of a loss of $1.72. This compares to loss of $1.41 per share a year ago.
zacks.com
- 2 months ago
Anaptys Announces Participation in November and December Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
globenewswire.com
- 2 months ago
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update.
globenewswire.com
- 2 months ago
8. Profile
Summary
AnaptysBio, Inc. ANAB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 482 M
Dividend Yield
0.00%
Description
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Contact
10770 Wateridge Circle, San Diego, CA, 92121-5801
https://www.anaptysbio.com
IPO
Date
Jan. 26, 2017
Employees
117
Officers
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.
Chief Medical Officer
Ms. Priya Raina
Senior Vice President of Clinical Operations
Ms. Monique Da Silva
Senior Vice President of Corporate Affairs
Mr. Daniel R. Faga
President, Chief Executive Officer & Director
Mr. Dennis M. Mulroy
Chief Financial Officer
Mr. Douglas A. Rich M.B.A.
Senior Vice President of CMC
Ms. Beth Mueller
Senior Vice President of Human Resources
Dr. Martin Dahl Ph.D.
Senior Vice President of Research
Mr. Benjamin Stone
Chief Business Officer
Mr. Eric J. Loumeau
Chief Legal Officer